Keywords: PharmaMar, Centocor Ortho, Yondelis, Zeltia, Sarcoma, Ovarian cancer
PharmaMar/Centocor’s Yondelis gets five new approvals outside the European Economic Area
Article | 17 March 2010
Centocor Ortho Biotech Products, a Johnson & Johnson subsidiary that has licensed rights in certain markets for Yondelis (trabectedin) from PharmaMar, part of Spain’s Grupo Zeltia, says that the regulatory authorities in Israel, Panama and Ukraine have approved the drug for advanced soft tissue sarcoma (STS) in adults. Furthermore, the authorities in Paraguay and Azerbaijan have cleared the drug for platinum-sensitive recurrent ovarian cancer (ROC). Yondelis is already approved for STS in Paraguay and Azerbaijan.
Zeltia recently reported 2009 sales of (123.4 million euros ($169.8 million) in 2009, up 17.2% on 2008, with Biopharmaceutical revenues expanded 53.3% due primarily to sales of Yondelis, which totaled 44.12 million euros last year. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
